Free shipping on all orders over $ 500

Telatinib

Cat. No. M1994

All AbMole products are for research use only, cannot be used for human consumption.

Telatinib Structure
Synonym:

BAY 57-9352

Size Price Availability Quantity
5mg USD 50  USD50 In stock
10mg USD 70  USD70 In stock
50mg USD 240  USD240 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Telatinib inhibits VEGFR2 autophosphorylation in a whole-cell assay with an IC50 of 19 nM. Telatinib (BAY 57-9352) blocks PDGF-stimulated growth of human aortic smooth muscle cells with an IC50 of 249 nM. Telatinib treatment significantly inhibits tumor growth and metastasis by blocking the VEGFR signaling and subsequently tumor angiogenesis. Administration of Telatinib as a single agent exhibits a potent anti-tumor activity in multiple human tumor xenograft models including MDA-MB-231 breast cancer, DLD-1 colon cancer and H460 non-small cell lung cancer.

Chemical Information
Molecular Weight 409.83
Formula C20H16ClN5O3
CAS Number 332012-40-5
Solubility (25°C) DMSO 70 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mross K, et al. Vasc Cell. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

[2] Langenberg MH, et al. Clin Cancer Res. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

[3] Steeghs N, et al. Invest New Drugs. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.

(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.

  Catalog
Abmole Inhibitor Catalog




Keywords: Telatinib, BAY 57-9352 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.